摘要
目的分析吉西他滨+顺铂+地塞米松(GDP)方案在淋巴瘤患者中的疗效及对生存期的影响。方法选取2010年1月~2012年12月医院收治的50例复发性NK/T细胞淋巴瘤患者作为观察对象,按照数字表法随机分为观察组与对照组,每组25例。观察组使用GDP化疗方案,对照组采用异环磷酰胺+卡铂+依托泊苷(ICE)化疗方案。观察两组患者的临床疗效、不良反应发生率,并随访5年观察两组患者的生存率及中位生存期。结果观察组25例患者中,完全缓解7例,部分缓解9例,稳定6例,进展3例,总治疗有效率为64.0%;对照组25例患者中,完全缓解8例,部分缓解7例,稳定5例,进展5例,总治疗有效率为60.0%,组间比较差异无统计学意义(P>0.05)。观察组不良反应发生率明显低于对照组(P<0.05)。观察组中位生存期为(19.6±2.4)月,2年生存率为32.5%;对照组中位生存期为(19.1±0.6)月,2年生存率为29.8%,两组生存率比较差异无统计学意义(P>0.05)。结论 GDP化疗方案在复发性NK/T细胞淋巴瘤患者中有一定的临床疗效,且安全性高于ICE化疗方案,适用于老年淋巴瘤患者的临床治疗。
Objective To analyze the effect of GDP chemotherapy on patients with lymphoma and its influence on survival time. Meth- ods 50 patients with recurrent NK/T cell lymphoma in our hospital from January 2010 to December 2012 were collected as subjects and were randomly divided into observation group and control group, 25 patients for each group. The observation group was treated with GDP chemotherapy, while the control group was treated with ICE chemotherapy. The clinical efficacy and adverse reactions of two groups were observed, and the survival rate and median survival time of the patients in the two groups were observed by follow-up for five years. Results In observation group, 7 patients achieved complete remission, 9 patients got partial remission, 6 patients were stable and 3 patients became worsen; the total effective rate was 64%. In the control group, 8 patients achieved complete remission, 7 patients achieved partial remis- sion, 5 patients were stable and 5 patients became worsen; the total effective rate was 60%. There were no statistically significant differences in total effective rate between the two groups. The incidence of adverse reactions in observation group was obviously lower than in control group （P 〈 0.05）. During follow-up, the median survival time of the observation group was （19.6± 2.4） months and two-year survival rate was 32.5%. In control group, the median survival time was （19.1 ±0.6） months and two-year survival rate was 29.8%. The survival rates of the two groups had no significant difference （P 〉 0.05）. Conclusion GDP chemotherapy has a certain clinical efficacy in patients with lymphoma, and the safety is higher than that of ICE chemotherapy regimen.
出处
《肿瘤药学》
CAS
2017年第4期488-492,共5页
Anti-Tumor Pharmacy
基金
江西省科技计划项目(2013BBG70051)
关键词
GDP化疗方案
淋巴瘤
临床疗效
生存期
GDP chemotherapy regimen
Lymphoma
Clinical efficacy
Survival time
